Skip to main content
رجوع
CLDX logo

Celldex Therapeutics, Inc.

جودة البيانات: 100%
CLDX
NASDAQ Healthcare Biotechnology
KWD 31.80
▲ KWD 0.90 (2.91%)
القيمة السوقية: 2.12B
نطاق اليوم
KWD 31.76 KWD 34.51
نطاق 52 أسبوعًا
KWD 14.40 KWD 34.51
حجم التداول
1,447,271
متوسط 50 يوم / 200 يوم
KWD 26.77 / KWD 24.92
الإغلاق السابق
KWD 30.90

تاريخ السعر

الاتجاهات المالية

مقارنة الأقران

مقابل وسيط قطاع Healthcare (626 نظير)

المقياس السهم وسيط القطاع
P/E -8.2 0.4
P/B 4.0 2.9
ROE % -40.6 3.7
Net Margin % -17253.3 3.8
Rev Growth 5Y % -24.6 10.0
D/E 0.0 0.2

النقاط الرئيسية

Revenue declined -24.64% annually over 5 years
Debt/Equity of 0.00 — conservative balance sheet
Negative free cash flow of -213.66M
Revenue growth is decelerating — 1Y growth trails 5Y average by 53.99%
Capital intensive — 180.93% of revenue goes to capex

النمو

Revenue Growth (5Y)
-24.64%
Revenue (1Y)-78.63%
Earnings (1Y)N/A
FCF Growth (3Y)N/A

الجودة

Return on Equity
-40.62%
ROIC-40.71%
Net Margin-17253.33%
Op. Margin-19160.00%

الأمان

Debt / Equity
0.00
Current Ratio10.49
Interest Coverage0.00

التقييم

P/E Ratio
-8.18
P/B Ratio4.02
EV/EBITDAN/A
Dividend Yield0.00%

All Fundamental Metrics

Growth
Revenue Growth (1Y) -78.63% Revenue Growth (3Y) -53.32%
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) -24.64% Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) 1.50M Net Income (TTM) -258.80M
ROE -40.62% ROA -44.39%
Gross Margin 100.00% Operating Margin -19160.00%
Net Margin -17253.33% Free Cash Flow (TTM) -213.66M
ROIC -40.71% FCF Growth (3Y) N/A
Safety
Debt / Equity 0.00 Current Ratio 10.49
Interest Coverage 0.00 Dividend Yield 0.00%
Valuation
P/E Ratio -8.18 P/B Ratio 4.02
P/S Ratio 1411.21 PEG Ratio -0.12
EV/EBITDA N/A Dividend Yield 0.00%
Market Cap 2.12B Enterprise Value 2.09B

Income Statement

Annual, most recent first

Income statement data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 1.50M 7.02M 6.88M 2.36M 4.65M
Net Income -258.80M -157.86M -141.43M -112.33M -70.51M
EPS (Diluted) -3.90 -2.45 -2.92 -2.40 -1.64
Gross Profit 1.50M -156.53M -111.13M -79.90M -48.66M
Operating Income -287.40M -195.08M -154.54M -115.23M -71.24M

Balance Sheet

Annual, most recent first

Balance sheet data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 582.98M 792.34M 465.63M 352.74M 444.65M
Total Liabilities 55.82M 45.34M 36.46M 26.53M 25.18M
Shareholders' Equity 527.17M 747.01M 429.17M 326.20M 419.48M
Total Debt 2.34M 3.81M 2.54M 4.03M 3.04M
Cash & Equivalents 28.87M 28.36M 34.81M 29.43M 39.14M
Current Assets 534.66M 747.16M 431.69M 317.69M 410.84M
Current Liabilities 50.99M 39.50M 31.13M 18.61M 16.53M